Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
Ingo K. Mellinghoff(Memorial Sloan Kettering Cancer Center), Paul S. Mischel(University of California, Los Angeles), Dennis J. Chute, P. Nagesh Rao, Maria Y. Wang, Charles L. Sawyers(Memorial Sloan Kettering Cancer Center), Rameen Beroukhim(Broad Institute), Michael D. Prados(University of California, San Francisco), Julie H. Huang(Institute of Human Genetics), Jeffrey C. Lee(Broad Institute), Bridget L. Riggs, William R. Sellers(Broad Institute), Koji Yoshimoto(Kyushu University), Timothy F. Cloughesy(University of California, Los Angeles), Timothy C. Peck(Broad Institute), Webster K. Cavenee(University of California San Diego), Linda M. Liau(University of California, Los Angeles), Ederlyn Q. Dia, David Stokoe(Enzo Life Sciences (United States)), Daphne A. Haas‐Kogan(Brigham and Women's Hospital), Shaojun Zhu, Steve Horvath(University of California, Los Angeles), Kan Lu(Guangxi University), Igor Vivanco(Royal Marsden NHS Foundation Trust)
Cited by 1,447
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k